Core Viewpoint - The domestic blood products industry is expected to maintain steady growth in the issuance of batches for albumin, intravenous immunoglobulin (IVIG), and fibrinogen by 2025, with an increase in the proportion of domestic albumin batch issuances compared to the previous year [1] Industry Summary - The issuance growth rate for factor VIII and prothrombin complex concentrate (PCC) is accelerating, while the issuance of rabies immunoglobulin and anti-rabies immunoglobulin is also showing good growth [1] - Due to centralized procurement and other factors, some domestic companies have adjusted the bidding prices for products like albumin and factor VIII, which is beneficial for increasing sales volume through price adjustments [1] - Companies are continuously advancing their research and development pipelines, focusing on recombinant products and new types of immunoglobulins, including chromatographic IVIG and subcutaneous immunoglobulin [1] - By 2026, the industry is advised to pay attention to the expansion of plasma stations, trends in industry mergers and acquisitions, and progress in new product development [1] - Companies that are at the forefront of the industry and are expected to continue expanding plasma station resources through both organic growth and external integration should be closely monitored for sustained growth in blood product business [1]

Investment Rating - The industry investment rating is "Outperform the Market" [3][23]. Core Insights - The blood products sector underperformed the market in September, primarily due to short-term performance pressures and changes in market sentiment. Long-term focus should remain on leading companies' plasma stations and R&D progress [1][21]. Summary by Sections Market Review - In September, the pharmaceutical and biological index fell by 1.71%, underperforming the CSI 300 index. The blood products sector specifically declined by 4.86% [1][14]. - Year-to-date, the blood products sector has seen a decline of 7.32% [15]. - Key blood product companies experienced significant stock price drops in September, with declines ranging from 2.76% to 8.59% [19]. Monthly Perspective on Blood Products - The decline in blood product stock prices since the beginning of 2025 is attributed to short-term performance pressures and market sentiment shifts. Price reductions in blood products have led to decreased gross margins and cash flow pressures for companies [21]. - The industry is undergoing accelerated consolidation, with leading companies leveraging mergers and acquisitions to strengthen their market position [21]. - Key areas of focus for the blood products sector include: 1. Plasma station resources and integration capabilities, as upstream plasma resources remain a core barrier to entry [21]. 2. Upgrading product structures to increase the proportion of high-margin products like coagulation factors and new products such as recombinant products and subcutaneous immunoglobulin [21]. 3. Monitoring price changes in blood products over the coming months [21]. 4. Advancements in new technologies for recombinant human serum albumin production using plant or yeast expression systems [21].